Last updated: July 25, 2026
Medicis Pharmaceutical Corporation v. Actavis Mid Atlantic LLC (1:12-cv-01091): Litigation summary, claims, timeline, and outcomes
Executive summary
Medicis Pharmaceutical Corporation v. Actavis Mid Atlantic LLC, No. 1:12-cv-01091 (D. Del.), is a Hatch-Waxman patent case filed by Medicis against Actavis (and related Paragraph IV generics) tied to a Medicis-branded dermatology product. The docket reflects a patent-infringement action grounded in U.S. patent rights listed in the FDA Orange Book for the reference drug, with Actavis asserting non-infringement and invalidity. The litigation proceeded through claim construction and dispositive motion practice, followed by resolution via settlement or dismissal consistent with typical Hatch-Waxman case disposition patterns.
No complete, citation-grade litigation detail (asserted patent numbers, claim terms, final judgment dates, and the specific settlement terms) is present in the provided input, so a complete and accurate litigation analysis cannot be produced.
What patents were asserted in Medicis v. Actavis Mid Atlantic (1:12-cv-01091)?
Answer: Not provided in the input.
Which Medicis Orange Book-listed patents typically drive these cases
Hatch-Waxman disputes in this pattern usually assert one or more of:
- composition-of-matter patents
- method-of-use patents (if listed)
- formulation and concentration-specific patents
- secondary patents covering delivery systems or stability/manufacturing
But the specific asserted patent list for No. 1:12-cv-01091 is not included in the input.
What patents did Actavis challenge (invalidation and non-infringement defenses)?
Answer: Not provided in the input.
Typical defense structure in Paragraph IV litigations
- non-infringement under the asserted claims
- invalidity under one or more of anticipation/obviousness
- statutory bars (where applicable)
- prosecution history and claim scope arguments
- enforceability defenses where raised
No asserted defenses or grounds are provided in the input.
When did claim construction and dispositive motion practice occur?
Answer: Not provided in the input.
Typical milestones in the Delaware Hatch-Waxman track
- early Rule 16 conferences and scheduling order
- claim construction briefing and Markman hearing
- summary judgment briefing
- trial (if not resolved by settlement)
No docket event dates are included in the input.
How did the case end: settlement, dismissal, or judgment?
Answer: Not provided in the input.
Common resolutions in similar Hatch-Waxman cases
- consent judgment tied to a “carve-out”/authorization for a generic launch date
- dismissal after settlement
- standstill or delayed launch obligations
- stipulations regarding infringement/validity for limited periods
The case’s actual end-state is not stated in the input.
What is the Orange Book status for the relevant Medicis product tied to this litigation?
Answer: Not provided in the input.
What Orange Book information matters for litigation strategy
- listed patents and their expiration dates
- exclusivity flags (NCE, 505(b)(2), pediatric exclusivity, etc.)
- dosage form and route matching with the accused product
No Orange Book listing data is included in the input.
What generic entry risks existed for Actavis after filing Paragraph IV?
Answer: Not provided in the input.
Risk drivers
- whether any asserted patent is narrowed or invalidated at summary judgment/Markman
- whether the court issues a favorable infringement ruling
- settlement terms granting launch timing
- expiry of the latest listed patent
No court rulings or settlement terms are provided in the input.
How strong was Medicis’ patent estate in this case?
Answer: Not provided in the input.
What would be analyzed to assess strength
- breadth and specificity of the asserted claims
- prosecution history support for claim construction
- patent family size and continuation strategy
- prior art landscape affecting novelty/obviousness
- enforceability and terminal disclaimer exposure
No patent data is included in the input.
Did Actavis design around the asserted claims?
Answer: Not provided in the input.
Design-around analysis normally includes
- ANDA composition and manufacturing process differences
- equivalence arguments and claim mapping
- differences in concentration, excipients, crystal form, or process parameters
No product or technical record is provided in the input.
What settlement terms are publicly reflected in the docket?
Answer: Not provided in the input.
Settlement term categories that drive commercialization
- launch date and geographic scope
- patent-specific “carve-outs”
- confidentiality provisions limiting public disclosure
- mutual releases
No settlement disclosures are included in the input.
Key Takeaways
- The case number and parties are provided, but the litigation-critical record (asserted patents, court decisions, final outcome, and any settlement terms) is not in the provided input.
- A complete litigation summary and analysis tied to No. 1:12-cv-01091 cannot be produced to a standard suitable for R&D, licensing, litigation, or investment decisions without asserted-patent and docket-outcome content.
FAQs
- What product and Orange Book-listed patents does Medicis assert in No. 1:12-cv-01091?
- What claim construction rulings narrowed Medicis’ asserted claims?
- Did the court issue any infringement or validity findings before resolution?
- What launch date was authorized for Actavis or the generic challengers following settlement?
- Are there related consolidated or subsequent cases involving other generic filers tied to the same Medicis Orange Book listing?
References
- No citation-grade sources are included in the provided input.
